
Drug susceptibility testing for Mycobacterium tuberculosis: a narrative review
Review article Chang-Ki Kim Department of Laboratory Medicine, Seoul Clinical Laboratories, Yongin, Korea Correspondence to Chang-Ki Kim, E-mail: psoas95@gmail.com Ann Clin Microbiol 2025;28(4):26. https://doi.org/10.5145/ACM.2025.28.4.7Received on 7 December 2025, Revised on 14 December 2025, Accepted on 15 December 2025, Published on 20 December 2025.Copyright © Korean Society of Clinical Microbiology.This is an Open Access article which is freely available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Tuberculosis (TB) remains a major global health threat, and the emergence and spread of drug-resistant Mycobacterium tuberculosis continue to undermine control efforts. Multidrug-resistant and rifampicin-resistant TB (MDR/RR-TB) is associated with prolonged treatment, higher toxicity, increased costs, and poorer outcomes compared to susceptible TB, making rapid and accurate drug susceptibility testing (DST) essential for effective patient management and transmission prevention. This review summarizes the current methods for DST in TB, focusing on the principles, strengths, and limitations of phenotypic and molecular
